The 3rd China Pharmaceutical Innovation 100 Summit in 2024 was grandly held in Shanghai. The summit, guided by the China Association of Pharmaceutical Enterprises, was jointly organized by E Manager Pharma and Thermo Fisher Scientific (hereinafter referred to as Thermo Fisher). The theme of the summit was “Leading Innovation, Convergence for Success”, aiming to promote local pharmaceutical innovation in China and accelerate the globalization process through the joint efforts of the industry ecosystem.
Innovation and Policy Support: In 2024, various regions successively introduced policies to encourage the development of innovative drugs, promoting the rapid development of the domestic biopharmaceutical innovation industry. These policies not only promoted the research and development of local innovative drugs but also accelerated the increase in outbound licensing transactions, gradually integrating domestic biopharmaceutical companies into the international new drug research and development market. At the summit, Jiang Zhicheng, Global Executive Vice President of Thermo Fisher, emphasized the importance of global resources and innovative technology in promoting local technological progress and industrial ecosystem development through a video speech.
Conference Content and Exchange: The main forum of the summit released multiple reports covering in-depth exchanges on policy, market, technology, ecology, and clinical aspects. Leaders and scholars from Shanghai Science and Technology Commission, BeiGene, Shenzhen Polytechnic University, and the Chinese Academy of Medical Sciences shared the latest developments and future trends in China’s pharmaceutical innovation at the summit. Feng Shihan, President of Thermo Fisher China, also delivered a keynote speech, introducing Thermo Fisher’s achievements in target research, pipeline quality improvement, and global clinical trial service capabilities.
Industry Cooperation and Future Prospects: The conference also invited well-known biopharmaceutical companies such as Aisino Pharma, Hengrui Medicine, and Kangfang Biotech to discuss “Changes in the Pattern of Pharmaceutical Innovation in China and Responses”, exploring the roles and future development directions of capital, innovative enterprises, and large pharmaceutical companies in the industry changes. The conference paid special attention to the two hot topics of “innovation” and “going global”, inviting representatives from many domestic pharmaceutical companies and investors to share business practices and engage in dialogue exchanges.
Launching a New Cycle Cooperation Ecology Plan: At the summit, pharmaceutical companies jointly launched the “Create a New Cycle Cooperation Ecology Plan”, aiming to promote the innovation and transformation of biopharmaceutical origin and accelerate the commercialization and industrialization of innovative achievements. Thermo Fisher will hold “Thermo Fisher Innovation Acceleration Days” in multiple regional markets to assist the full process from research and development to commercial production, enhancing the competitiveness of pharmaceutical innovation.
Feng Shihan, President of Thermo Fisher China, stated that for the first time, the government has collectively included innovative drugs, biomanufacturing, and life sciences in the government work report and introduced policies to encourage new quality productivity, which has continuously brought development momentum to the Chinese biopharmaceutical market. Thermo Fisher will continue to uphold the commitment of “Leading Innovation, Convergence for Success” to help enhance the product development capabilities of local innovative pharmaceutical companies in China, accelerate the globalization process, and benefit global patients with more high-quality innovative therapies.
Tan Yong, series media producer of E Manager Pharma, pointed out that the China Pharmaceutical Innovation 100 Summit has been held for three consecutive sessions. Although facing challenges such as funding shortages during this period, significant achievements have also been made. By building a platform for cooperation and exchange among innovators, the event aims to improve the innovation ecosystem and promote in-depth exchanges at the technical and cooperation levels.
Comments are closed